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Abstract
Background
Meteorin (METRN) is a recently described neutrophic factor with angiogenic properties.
This is a nested case-control study in a longitudinal cohort study that describes the serum
profile of METRN during different periods of gestation in healthy and preeclamptic pregnant
women. Moreover, we explore the possible application of METRN as a biomarker.
Methods and Findings
Serum METRN was measured by ELISA in a longitudinal prospective cohort study in 37
healthy pregnant women, 16 mild preeclamptic women, and 20 healthy non-pregnant
women during the menstrual cycle with the aim of assessing serum METRN levels and its
correlations with other metabolic parameters. Immunostaining for METRN protein was per-
formed in placenta. A multivariate logistic regression model was proposed and a classifier
model was formulated for predicting preeclampsia in early and middle pregnancy. The per-
formance in classification was evaluated using measures such as sensitivity, specificity,
and the receiver operating characteristic (ROC) curve. In healthy pregnant women, serum
METRN levels were significantly elevated in early pregnancy compared to middle and late
pregnancy. METRN levels are significantly lower only in early pregnancy in preeclamptic
women when compared to healthy pregnant women. Decision trees that did not include
METRN levels in the first trimester had a reduced sensitivity of 56% in the detection of pre-
eclamptic women, compared to a sensitivity of 69% when METRN was included.
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Conclusions
The joint measurements of circulating METRN levels in the first trimester and systolic blood
pressure and weight in the second trimester significantly increase the probabilities of pre-
dicting preeclampsia.
Introduction
Pregnancy is a period during which a woman experiences a series of anatomical, histological,
hormonal, and metabolic changes that facilitate the development of a new human being [1]. As
part of this process, it is necessary that a proper maternal-fetal interaction is developed so that
the fetus can receive all the nutrients needed for growth [2]. Therefore, a balance between the
angiogenic and anti-angiogenic processes in the placenta is critical because this new vascular
network will be in charge of the fetal metabolic support, ensuring its viability [3].
During pregnancy, angiogenesis is an important and complex process involving several
families of growth factors. Among these, two of the most documented are the family of vascular
endothelial growth factor-A (VEGF-A) and the family of fibroblast growth factor-2 (FGF-2)
[4,5]. On the other hand, meteorin (METRN) is a recently described neurotrophic factor that
does not share homologous motifs with VEGF-A or FGF-2, thus forming a new family, named
meterorin-like (METRNL), which conserves about 40% of its identity [6]. METRN is a secreted
protein widely expressed in adult mouse organs [7,8]. It also promotes the formation of GFAP-
positive glia via activation of the Jak-STAT3 pathway [9,10]. In addition to its role as a neuro-
trophic factor, METRN has been described as an important factor in attenuating angiogenesis
at the gliovascular interface [8].
Preeclampsia is a leading and direct cause of maternal and infant morbidity and mortality
worldwide. It consists of a multisystemic disorder between the maternal condition and the feto-
placental unit [11]. An imbalance in the ratio of angiogenic / anti-angiogenic factors is a well
characterized feature of preeclampsia [11] and the implications that this imbalance may have
in the occurrence of long-term complications in the offspring is not yet clear. Since METRN is
a secreted protein that attenuates angiogenesis in astrocytes [8], we hypothesized that circulat-
ing METRN levels might be altered during normal pregnancy and preeclampsia. In the present
work, using a longitudinal cohort study, we describe for the first time the serumMETRN pro-
file in pregnant women during different periods of normal pregnancy and in preeclamptic
women. Thus, this study contributes to the understanding of the potential role of METRN in
the physiology and pathology of pregnancy.
Materials and Methods
Subjects and Study design
The Ethics Committees of the Universidad Nacional de Colombia and the Hospital of Engativá
approved this study. Written informed consent was provided by each of the women who par-
ticipated in the study, with all the participants signing the informed consent to be included and
could leave at any time. Also, the ethics committees followed this study and ensured participant
safety during this investigation. This study was conducted by the Departments of Physiology
and Obstetrics and Gynecology of the Faculty of Medicine of the Universidad Nacional de
Colombia and Departments of Physiology of the University of Santiago de Compostela–Spain,
and included pregnant patients of the Hospital of Engativá (Bogotá, Colombia).
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We conducted a nested case-control study in the longitudinal cohort. Women were
included in this study between the 11th and 13th week of gestation, determined by ultrasound
and last menstrual period. This study included 37 healthy pregnant women, with no medical or
obstetrical complications, delivering at term during the period of 2012–2014, whom were stud-
ied during early (11.6–12.6 weeks), middle (24.2–24.6 weeks) and late pregnancy (34.1–35.1
weeks) (Table 1).
Also, 16 women of the same longitudinal cohort who developed mild preeclampsia were
included in this study (Table 1). The diagnosis of preeclampsia was defined as a persistent (> 6
h) high blood pressure> 140/90 mmHg, and proteinuria was defined as a urine protein
concentration> 30 mg/dL in at least two specimens collected at least 4 hours apart, as
Table 1. Clinical and biochemical characteristics of normal pregnant and preeclamptic women.
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0.018 11.1 (+/- 4.6) 15.8 (+/- 6) 0.01 14.3 (+/- 5.3) 13.9(+/- 5.1) 0.807




























0.793 232.8(+/- 70.6) 240.5 (+/- 76) 0.731
METRN. ng/mL (mean
+/-SD)
26.9(+/- 2.2) 24.2 (+/- 2.1) 0.000 24.9 (+/- 2.3) 25 (+/- 1.9) 0.939 25.2(+/- 2.2) 24.6(+/- 1.9) 0.330
EP: Early Pregnancy, MP: Middle Pregnancy, LP: Late Pregnancy, PE: Preeclamptic. Data with normal distribution were reported as mean +/- standard
deviation (SD), while data with non-normal distribution were reported as median and interquartile range (IQR). A p-value < 0.05 was considered
statistically significant.
doi:10.1371/journal.pone.0131013.t001
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described elsewhere [12]. Furthermore, the diagnosis of preeclampsia was confirmed by deter-
mining serum levels of the following factors: soluble endoglin (sEng) (ab100507), placental
growth factor (PlGF) (ab100629), and soluble vascular endothelial growth factor receptor 1
(sVEGFR-1) (ab119613) [13]. Pregnant women with normal outcomes were used as a control
(data not shown). The human ELISA kits were purchased from Abcam and the sample concen-
trations (ng/ml) utilized were in accordance with the manufacturer’s protocols.
Additionally, 20 young healthy non-pregnant women were studied during the follicular
(3rd–5th day) and luteal phase (21st–23rd day) of the menstrual cycle (Table 2). The recruit-
ment of healthy non-pregnant women occurred during the same period of recruitment as the
other groups. The inclusion and exclusion criteria for participation in the study have been
described elsewhere [12]. The demographic and clinical features of all the women are described
in Table 1 and Table 2.
Laboratory assays
Whole venous blood was drawn from the upper arm into BD Vacutainer serum tubes. Samples
were centrifuged at 3000g for 10 minutes at 4°C and serum was aspirated out, aliquoted, and
stored at -80°C until biochemical and hormonal assays were performed. Total cholesterol,
HDL cholesterol, triglycerides, glucose, and insulin were measured (LIAISON Analyzer, Salu-
ggia, Italy). Homeostasis Model Assessment–Estimated Insulin Resistance (HOMA-IR) was
calculated according to Matthews’ et al formula [12]. Additionally, serum progesterone levels




Age, years (median (IQR)) 23 (20–26)
Body mass index, Kg/m2 (mean +/- SD) 21.4 (+/- 2)
Insulin, uUI/mL (median (IQR)) 6 (4.4–12.5)
Glucose, mg/dL (mean +/- SD) 82 (+/- 6.2)
HOMA IR (median (IQR)) 1.2 (0.8–2.7)
Total cholesterol, mg/dL (mean +/- SD) 167.8 (+/- 22.9)
HDL-chol, mg/dL (mean +/- SD) 47.3 (+/- 10.9)
Triglycerides, mg/dL (mean +/- SD) 73.2 (+/- 19.2)
Progesterone, ng/mL (mean +/- SD) early follicular (cycle
day 4 +/- 1)§
0.6 (+/- 0.2) <0.0001b
Progesterone, ng/mL (mean +/- SD) median luteal (cycle
day 22 +/- 1)§
10.1 (+/- 5.9)
METRN, ng/mL (mean +/- SD) early follicular (cycle day 4 +/-
1)Ϯ
23.3 (+/- 2.9) 0.2801c
METRN, ng/mL (mean +/- SD) median luteal (cycle day 22
+/- 1)Ϯ
24.1 (+/- 2.1)
a The difference between group means (early follicular and median luteal phases) was tested on
progesterone and METRN levels. Only progesterone levels are significantly different between early
follicular and median luteal phases (p<0.0001). Data with normal distribution were reported as mean +/-
standard deviation (SD), while data with non-normal distribution were reported as median and interquartile
range (IQR).
b Progesterone determination in the two different phases of the menstrual cycle.
c Meteorin measurement in luteal and follicular phase.
doi:10.1371/journal.pone.0131013.t002
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in healthy non—pregnant women during the luteal and follicular phases of the menstrual cycle
were measured (Roche Elecsys 1010 Immunoanalyzer, Boulder,Colorado, USA).
The measurement of serum METRN concentrations was determined using a commercially
available ELISA (Uscn Life Science Inc. Cat # SEH662Hu). The detection range of METRN was
0.156–10 ng/mL. Inter and intra-assay variation coefficient was 9% and 10% respectively.
Additionally, the METRN concentration of each sample was analyzed in duplicate and the
mean of the two measurements for each sample were reported in the statistical analysis.
METRN immunohistochemistry in human placenta
Immunostaining for METRN was performed in embedded human adipose tissue and placenta.
These paraffin blocks were provided from the Services of the Department of Pathology, Faculty
of Medicine, at the Universidad Nacional de Colombia. Placental samples from patients at
week 11 of gestation (from spontaneous abortion without histopathological alterations) were
analyzed as described elsewhere [14].
Polyclonal rabbit anti–METRN antibodies (Abcam–Anti-METRN antibody–ab131619)
were employed for the immunostaining, using a method described elsewhere [12]. With respect
to the negative control a non-specific rabbit IgG was used in place of the primary polyclonal
rabbit anti-METRN antibody in each immunohistochemistry placental specimen.
Choice of criteria for predictive algorithm for preeclampsia assessment
In general terms, the diagnosis of preeclampsia was based on the criteria set forth by the Amer-
ican College of Obstetrics and Gynecology (ACOG). Based on the recommendations of the
Task Force on Hypertension in Pregnancy by the American College of Obstetricians and Gyne-
cologists, and due to the nature of preeclampsia, this expert committee eliminates the depen-
dence on the presence or absence of proteinuria for the diagnosis of preeclampsia [15].
Therefore, in the absence of proteinuria preeclampsia is diagnosed in association with other
clinical features of the syndrome such as: thrombocytopenia (a platelet count below 100,000 /
uL), impaired liver function (altered levels of liver transaminase, doubling its normal value),
development of renal failure (elevated levels of serum creatinine greater than 1.1mg / dL or a
doubling of serum creatinine in the absence of other renal disease), pulmonary edema, or cere-
bral or visual disturbances [15]. This recommendation is due largely to a percentage of cases
diagnosed with preeclampsia, in which proteinuria is undetected or of late onset [16]. In addi-
tion to the clinical monitoring of the patients in this cohort study, the characterization of this
subpopulation was based on the analysis of serum pro and anti-angiogenic factors previously
documented as early predictors of this disease. Based on previously described soluble endoglin
(sEng), placental growth factor (PlGF) and soluble vascular endothelial growth factor receptor
1 (sVEGFR-1), on the serum profile both for normal pregnant and pregnant women diagnosed
with preeclampsia was determined, and was found to be in agreement with what has already
been reported by Romero et al. [13].
Statistical Analysis
The data were analyzed using R software (version 3.0.3). The difference between group means
(preeclampsia and normal) was tested on the demographic and clinical features at each preg-
nancy trimester. The Student's t-test was used when the variables were normally distributed;
otherwise, the non-parametric Wilcoxon-Mann-Whitney test was used. Some variables were
transformed to the natural logarithm to assure normal distribution. The normal distribution of
data was verified using the Shapiro-Wilk test. A p-value< 0.05 was considered statistically sig-
nificant. Data with normal distribution were reported as mean +/- standard deviation (SD),
SerumMeterorin Levels during Pregnancy
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while data with non-normal distribution were reported as median and interquartile range
(IQR).
A univariate analysis was performed to examine the correlation between serumMETRN
levels and the variables throughout pregnancy. Univariate correlations were assessed on the
normal group by partial Spearman’s correlation coefficient with adjustment for gestational age.
With the aim of identifying independent relationships between the variables and pre-
eclampsia, a multivariate logistic regression model was proposed. The logit model was selected
to explain the odds of suffering preeclampsia as a function of the anthropometric and meta-
bolic variables in the study. The Akaike information criterion (AIC) was used to select the
parameters that best explain the variability in the dependent variable. Afterwards, the 95% con-
fidence intervals for the odds of preeclampsia were assessed on significant parameters.
As a final step in our methodology, a classifier model was formulated for predicting pre-
eclampsia in early and middle gestational ages, i.e first and second trimesters. The classification
between preeclamptic and normal pregnant women was based on a decision tree approach.
The decision tree was constructed in Weka (version 3.6.10) [17] using the J48 algorithm [18]
with a 10-fold cross validation for testing predictions. Those variables showing significant dif-
ferences between group means were included in the model. Moreover, their variations (delta
variables) between the first and second trimesters were included. The performance in classifica-
tion was evaluated using measures such as sensitivity, specificity, and the receiver operating
characteristic (ROC) curve [19].
Results
Immunohistochemistry of METRN protein in human placenta
METRN immunostaining was observed in immature mesenchymal decidua and villi from first
trimester human placenta (Fig 1A, 1B and 1C, respectively). Moderate cytoplasmic immunore-
activity was observed in cytotrophoblast, syncytiotrophoblast, and decidual cells. A non-spe-
cific rabbit IgG was used as a negative control in place of the primary polyclonal rabbit anti-
METRN antibody in each immunohistochemistry placental specimen (Fig 1).
SerumMETRN levels in healthy non-pregnant women, normal pregnant
and preeclamptic women
Measurement of clinical and biochemical characteristics of healthy and preeclamptic pregnant
women and healthy non—pregnant women are shown in Tables 1 and 2. In addition, the char-
acterization of preeclamptic subpopulation was based on the analysis of serum pro and anti-
angiogenic factors, soluble endoglin (sEng), placental growth factor (PlGF) and soluble vascu-
lar endothelial growth factor receptor 1 (sVEGFR-1), and was found to be in agreement with
what has already been reported by Romero et al. (data not shown) [13].
SerumMETRN levels were significantly higher in the first stage of gestation when compared
to healthy non—pregnant women (Fig 2 and Fig C in S1 Fig). Circulating METRN levels were
also significantly higher in the first trimester in comparison to the second and third trimesters
of pregnancy (p<0.01) (Fig 2 and Table 1). Additionally, METRN levels in middle and late
pregnancy were similar to the ones obtained in non-pregnant women (Fig 2). No statistically
significant associations were observed between METRN concentrations in early pregnancy
(EP) compared to middle (r = -0.043, P = 0.804) (MP) and late pregnancy (r = -0.266,
P = 0.122) (LP) (Figs A and B in S1 Fig, respectively). In these figures, most of the patients are
under the solid line (y = x), endorsing the conclusion that MERTN levels tend to be higher in
EP than in MP or LP. Additionally, a dot plot for EP serumMETRN concentration in normal
SerumMeterorin Levels during Pregnancy
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pregnancy and eumenorrheic women (EW) is shown in Fig C in S1 Fig. The bar means values
are also shown. As stated before, there is a significant difference between the groups
(P<0.001).
Furthermore, serumMETRN levels were significantly higher in normal pregnant women in
comparison to the preeclamptic pregnant women during the early period of gestation (p
<0.0001) (Fig 3 and Table 1). However, no significant differences were found in serum
METRN levels between normal pregnant women and preeclamptic pregnant women in the
second and third trimesters (p>0.05) (Fig 3).
Fig 1. METRN immunohistochemisty in human placenta. Human placenta in the first trimester of
pregnancy (spontaneous abortion) in which immature mesenchymal villi of first trimester decidua are
illustrated. Moderate cytoplasmic immunoreactivity for METRN was observed in cytotrophoblast cells,
syncytiotrophoblast cells and decidual cells (20x). A non-specific rabbit IgG was used as negative control in
place of the primary polyclonal rabbit anti-METRN antibody in each immunohistochemistry placental
specimen.
doi:10.1371/journal.pone.0131013.g001
Fig 2. SerumMETRN levels in the three trimesters of pregnancy and in a group of eumenorrheic
woman. The highest levels of METRN are observed in early pregnancy (EP) and then decline with advancing
gestation in the subsequent periods, in middle pregnancy (MP), and late pregnancy (LP), with this reduction
in serumMETRN being statistically significant (p <0.01). Moreover, significant differences were observed
when comparing serumMETRN in the groups of eumenorrheic women (EW) and EP (p <0.001).
doi:10.1371/journal.pone.0131013.g002
SerumMeterorin Levels during Pregnancy
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Correlations between serumMETRN levels and clinical and biochemical
features
In normal pregnant women, univariate partial correlations were performed between serum
METRN levels and the different clinical/biochemical parameters observed (S1 Table). Serum
METRN levels were adjusted for gestational age in the univariate correlation analysis. Partial
correlation analysis after adjustment showed that serumMETRN levels concentrations were
negatively associated with glucose levels (r = -0.39, p = 0.01) and positively associated with tri-
glyceride levels (r = 0.34, p = 0.03) only in the first period of gestation. In contrast, serum
METRN levels were not significantly correlated with weight, BMI, systolic blood pressure
(SBP), diastolic blood pressure (DBP), mean arterial pressure, insulin, HOMA-IR, total choles-
terol, HDL-cholesterol, and LDL cholesterol in any of the periods that were studied (S1 Table).
Fig 3. SerumMETRN levels in healthy and preeclamptic women during pregnancy. A significant
decrease in serumMETRN in the group of mild preeclamptic pregnant women is observed when compared
with the group of healthy pregnant women at the onset of pregnancy (EP) (p <0.001). The other periods
analyzed did not show significant variations in serumMETRN levels.
doi:10.1371/journal.pone.0131013.g003
Fig 4. Classifier model based on decision trees.Decision nodes are represented by circles. Decision
nodes show the significant variables used to perform the classification: EP-METRN (METRN levels in early
pregnancy), MP-SBP (systolic blood pressure in middle pregnancy), MP-Weight (weight in middle
pregnancy), ΔWeight (delta of weight between middle and early pregnancy: ΔWeight = MP.weight–EP.
weight) and ΔSBP (Delta of Systolic Blood Pressure between middle and early pregnancy: ΔSBP = MP.
SBP–EP.SBP). Each branch represents a test given to the decision node. Leaf nodes are represented by
squares. Leaf nodes show the class in which a patient is classified (normal or preeclampsia). Leaf nodes also
show the total of women from the cohort that were properly classified / total of women from the cohort
misclassified.
doi:10.1371/journal.pone.0131013.g004
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PLOS ONE | DOI:10.1371/journal.pone.0131013 June 29, 2015 8 / 12
Logistic regression analysis with preeclamptic condition as dependent
variable
A logistic regression model was formulated and the parameters were summarized in S2 Table.
The logit model links the binary response preeclampsia or not preeclampsia as a function of
the predictors: gestational age (early, middle, or late pregnancy), BMI, SBP, triglycerides, and
METRN levels. All these variables were found to be significant in explaining the odds of pre-
eclampsia and a 95% confidence interval was assessed. In this logistic regression analysis, it
should be noted that the odds of preeclampsia decrease between 1% and 35% when the
METRN level increases 1ng/mL (S2 Table).
Predictive algorithm for preeclampsia assessment
A tree based approach was implemented to diagnose preeclampsia before the third period of
pregnancy. We selected variables that showed significant differences (Table 1) in early preg-
nancy (weight, SBP, insulin, METRN, and HOMA) and middle pregnancy (weight, SBP, insu-
lin, METRN, HOMA-IR, and HDL-cholesterol). In addition, the delta variables (weight, SBP,
insulin, and HOMA-IR) were included (see statistical analysis). After applying the J48 algo-
rithm, only noteworthy variables were included in the decision tree (Fig 4). The decision tree
performs worthwhile classifications in both normal and preeclamptic conditions (S3 Table).
After testing the decision tree with cross-validation, it shows a sensitivity of 69% and specificity
of 76% in detecting preeclampsia. Moreover, the area under the ROC curve is 0.73, confirming
a good level of accuracy in the classification (S2 Fig).
SerumMETRN levels in early pregnancy is the first decision node (top of the tree) and
therefore, the most important variable to classify. The classifier model proposes a critical
METRN level of 23.8ng/mL. In the longitudinal cohort, ten out of sixteen women under the
critical METRN levels developed preeclampsia (<23.8ng/mL). These ten women showed either
high SBP in middle pregnancy (>98mm Hg) or a high increase of weight (Δweight> 5kg).
The decision tree shows that all ten women under the critical METRN level were properly
classified.
On the other hand, we found six preeclamptic women whose METRN levels exceeded the
threshold (>23.8 ng/mL) in early pregnancy. These women showed not only increased weight
in middle pregnancy (>63kg) but also their ΔSBP decreased considerably (ΔSBP< -5mmHg).
In the decision tree, the classification over the right path is slightly less accurate (Fig 4). Five
preeclamptic women from the cohort were properly classified and one was misclassified.
Discussion
The results of this study reveal for the first time that serumMETRN levels did not differ signifi-
cantly in non-pregnant women studied during the follicular and luteal phase of the menstrual
cycle. However, serumMETRN levels are significantly elevated in the first trimester in healthy
pregnant women whereas they decrease in the second and third trimesters reaching similar lev-
els to the ones observed in non-pregnant women. Conversely, serum levels of METRN
remained unchanged throughout gestation in preeclamptic women, being significantly lower
in the first period of gestation when compared with serum levels of healthy pregnant women.
Finally, we detected METRN protein immunoreactivity in the cytoplasm of cytotrophoblast
cells, syncytiotrophoblast cells, and decidual cells in first trimester placenta.
Recent studies have shown that METRN participates in cerebral angiogenesis [8] as well as
neurogenesis [4]. Previous studies in primary astrocytes identified expressed sequence tags that
were increased under re-oxygenation following hypoxia [20,21]. This hypoxia/reoxygenation
SerumMeterorin Levels during Pregnancy
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regulatory factor was identified as METRN. A previous study found that METRN blocks the
angiogenic activity of microvascular endothelial cells, by induction of thrombospondin-1/-2
expression in astrocytes [8]. Elevated serumMETRN levels in the first period of gestation
might contribute to the adaptation of the fetal placental vasculature to the increasing fetal
demands, enhancing the efficiency and high capacity of the maternal-fetal exchange system for
the growth and development of the fetus.
Although METRN is widely expressed in rodent tissues, most studies have specifically
focused on the functions of METRN in the central nervous system [6,9,22]. This is the first
study demonstrating protein expression levels of this gene in human placenta, suggesting that
METRN might play a critical role in controlling vascular angiogenesis and maturation in the
placenta. In addition, the present study shows a reduction in maternal serumMETRN levels
during the initial phase of gestation in preeclamptic women in comparison to healthy pregnant
women. Thus, it is plausible to hypothesize that reduced METRN levels contribute to the risk
of preeclampsia characterized by reduced placental vascular development, leading to poor pla-
cental function and fetal growth compromise [11,23].
Moreover, it is well documented the utility of pro and anti-angiogenic factors as serum bio-
markers in the early prediction of maternal and perinatal outcome. This is because one mecha-
nism related to the development of preeclampsia is the alteration in placental perfusion, which
leads to ischemia, a release of pro-inflammatory factors leading to platelet activation and endo-
thelial dysfunction, producing the underlying clinical characteristics of the disease. Thus, a dys-
regulation of pro and anti angiogenic factors has been described which contributes
significantly to the pathogenesis of preeclampsia, among these VEGF, sFlt-1, PlGF, endothelin,
and endoglin [24]. Therefore, systolic blood pressure, anthropometric variables, and serum
meteorin levels were established as significant in formulating the algorithm for the early pre-
diction of preeclampsia
In support of this hypothesis, and by means of a logistic regression analysis, the present
study shows that the odds of preeclampsia decrease between 1% and 35% when METRN levels
increase by 1ng/ml. Additionally, the classification tree (Fig 4) showed that serumMETRN lev-
els above / below 23.8ng/mL are crucial in the early detection of developing preeclampsia,
along with cutoff values for SBP (> 98mmHg) and weight ( 63kg) during middle pregnancy.
In the present study, in 50% of cases of preeclampsia in the analyzed longitudinal cohort,
METRN levels were lower than the critical value and were associated with high SBP in middle
pregnancy (> 98mmHg).
The decision tree showed that the variables SBP and weight, analyzed individually, are not
sufficient to classify a woman in the cohort as preeclamptic or normal. The inclusion of serum
METRN levels during early pregnancy significantly increases the sensitivity for classification.
Decision trees that did not include METRN had a reduced sensitivity of 56% in the detection of
preeclamptic women, compared to a sensitivity of 69% in the actual decision tree (S3 Table and
Fig 4). These observations point to a possible use of METRN as a potential biomarker for the
development of preeclampsia. Nevertheless further studies with different cohorts are needed in
order to corroborate these findings and to establish this parameter in the routine clinical set-
ting. In addition, our data also indicates the need of discovering new biomarkers that, added to
the decision tree assessed here, could increase the sensitivity of detection to levels that could
make the early detection the development of preeclampsia with total accuracy feasible in the
clinical setting.
SerumMeterorin Levels during Pregnancy
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Conclusion
In conclusion, this study demonstrates that: a) serumMETRN levels are unaltered throughout
the menstrual cycle in healthy non-pregnant women; b) first trimester human placenta shows
a specific immunostaining of METRN in the cytoplasm of cytotrophoblast, syncytotrophoblast,
and decidual cells; c) serumMETRN levels are increased in the first trimester in healthy preg-
nant women and remain unchanged throughout gestation in preeclamptic women; d) the mea-
surement of circulating METRN in the first trimester together with systolic blood pressure and
weight in the second trimester significantly increases the probabilities of predicting
preeclampsia.
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